Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918406 · ClinicalTrials.gov registry record · Phase 4
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
A Phase 4 study, sponsored by Oyster Point Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT05918406: Completed Phase 4 study, sponsored by Oyster Point Pharma.
NCT05918406 is a Phase 4 study that has completed, run by Oyster Point Pharma. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05918406, a Phase 4 study, has completed, sponsored by Oyster Point Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray
Primary Outcome
Number of Participants with Adverse Events with use of the nasal guide
Interventions
- COMBINATION_PRODUCT Nasal Guide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-14 |
| Est. Completion | 2023-08-18 |
| Phase | Phase 4 |
What the finished NCT05918406 record still lists
NCT05918406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Nasal Guide is the first listed.
NCT05918406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05918406 about?
NCT05918406 is a clinical study titled "Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya". The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray
What is the current status of trial NCT05918406?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-06-14. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT05918406?
The interventions under investigation include: Nasal Guide (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05918406?
This trial is sponsored by Oyster Point Pharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05918406's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI